Estrogen-progestin therapy in women after stem cell transplant

Abstract

Women undergoing stem cell transplantation (SCT) are mostly young and have more than 90% probability of ovarian failure, which is often permanent. A woman's age, use of radiotherapy and alkylating chemotherapy, and the allogeneic type of transplant are associated with a higher rate of premature ovarian failure and worse residual ovarian function. Premature ovarian failure has serious systemic and psychological effects that may need treatment and should be managed by practitioners trained to treat this particular population of women. Ultrasonographic evidence of ovarian follicles is often associated with a future resumption of cycles, but there are no serum markers to predict the return of ovarian function in these patients. In our center, the rate of ovarian function recovery was 7% after allogeneic SCT and 25% after autologous SCT (P<0.05). There are no guidelines on how to manage premature ovarian failure induced by myeloablative treatments followed by SCT. Because of the likelihood of the need for long-lasting estrogen plus progestin therapy (EPT) and the increased risk of secondary neoplasia after SCT, the EPT should be as physiological as possible. In our experience, the cyclical sequential combination of estradiol (2 mg daily) plus dydrogesterone (10 mg for 14 d/mo) was associated with excellent compliance because of its simple administration and few adverse effects. Such a treatment led to a dramatic improvement in vasomotor, urogenital, and psychological symptoms related to estrogen deficiency. However, in the allogeneic transplantation setting, up to 25% of women may suffer from gynecological chronic graft-versus-host disease, which may become apparent as hematocolpometra after introduction of EPT. Thus, accurate pretreatment evaluation and frequent monitoring during treatment are required. Moreover, EPT absorption may be reduced in patients who received allotransplants and have gastrointestinal or skin chronic graft-versus-host disease.

Hormone Replacement Therapy in Cancer Survivors – Review of the Literature

“…The studies that directly address the question of MHT after oncotherapy of malignant haematologic diseases found no increase in the recurrence of the disease or excess mortality, while significant alleviation of menopausal symptoms was demonstrated [100]. In summary, at least neutral effect of HRT on malignant haematologic diseases can be demonstrated, but most probably estrogen supplementation even exerts a positive effect on these diseases [101].…”

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

“…The genital tract of women has been documented to be a potential target for cGVHD; in fact, variable degrees of vulvovaginal lesions related to gynecological cGVHD were described in 25% of cases by ourselves and by a large recent multicentric Italian study including 213 women [34, 35]. Milder forms of cGVHD were characterized by an increased frequency of developing vulvovaginal infections and inflammation, while the more severe forms have been found responsible for vaginal and cervical stenosis and malformations of the internal and external genitalia and sometimes associated even with perineal involvement.…”

Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD

“…45,46 Only a minority (o 5%) of these patients recover ovarian function after HSCT for a limited period of time before entering early menopause. 47,48 Toxicity-reduced conditioning regimens applied in younger patients may reduce the incidence of POF but systematic review is currently pending.…”